RU2449990C2 - Индолы в качестве модуляторов 5-ht6 - Google Patents
Индолы в качестве модуляторов 5-ht6 Download PDFInfo
- Publication number
- RU2449990C2 RU2449990C2 RU2009103313/04A RU2009103313A RU2449990C2 RU 2449990 C2 RU2449990 C2 RU 2449990C2 RU 2009103313/04 A RU2009103313/04 A RU 2009103313/04A RU 2009103313 A RU2009103313 A RU 2009103313A RU 2449990 C2 RU2449990 C2 RU 2449990C2
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- indol
- phenylsulfonyl
- indole
- methoxy
- Prior art date
Links
- 0 C*(C)C(*)N(*)* Chemical compound C*(C)C(*)N(*)* 0.000 description 17
- ZYIBOEDPNJFYQN-UHFFFAOYSA-N CCCCCCS(N)(NCC)O Chemical compound CCCCCCS(N)(NCC)O ZYIBOEDPNJFYQN-UHFFFAOYSA-N 0.000 description 1
- PFFZTPGDNRINSP-UHFFFAOYSA-N CCN(CC)Cc1cccc2c1cc[n]2S(c1ccc[s]1)(=O)=O Chemical compound CCN(CC)Cc1cccc2c1cc[n]2S(c1ccc[s]1)(=O)=O PFFZTPGDNRINSP-UHFFFAOYSA-N 0.000 description 1
- HDWKZEVXDHCBCA-UHFFFAOYSA-N CN(C)Cc(c(cc1)c(cc2)[n]1S(c(cc1)cc3c1OCCCO3)(=O)=O)c2OC Chemical compound CN(C)Cc(c(cc1)c(cc2)[n]1S(c(cc1)cc3c1OCCCO3)(=O)=O)c2OC HDWKZEVXDHCBCA-UHFFFAOYSA-N 0.000 description 1
- OZPCHNRAULUSGK-SSDOTTSWSA-N C[C@H](CC(C)(C)S(C)(CO)=O)C(F)(F)F Chemical compound C[C@H](CC(C)(C)S(C)(CO)=O)C(F)(F)F OZPCHNRAULUSGK-SSDOTTSWSA-N 0.000 description 1
- DQTVJLHNWPRPPH-AYMMMOKOSA-N C[C@H]1[C@@H](C)[C@@H](C)CCC1 Chemical compound C[C@H]1[C@@H](C)[C@@H](C)CCC1 DQTVJLHNWPRPPH-AYMMMOKOSA-N 0.000 description 1
- WDWXGGQTKNYZFJ-UHFFFAOYSA-N Cc(c1c(CN(C)C)cccc11)c[n]1S(c1ccccc1)(=O)=O Chemical compound Cc(c1c(CN(C)C)cccc11)c[n]1S(c1ccccc1)(=O)=O WDWXGGQTKNYZFJ-UHFFFAOYSA-N 0.000 description 1
- XMQIYFHQXCGESD-UHFFFAOYSA-N Cc(cc1)ccc1S([n]1c2cccc(CC3CCNCCCCC3)c2cc1)(=O)=O Chemical compound Cc(cc1)ccc1S([n]1c2cccc(CC3CCNCCCCC3)c2cc1)(=O)=O XMQIYFHQXCGESD-UHFFFAOYSA-N 0.000 description 1
- JCCDLZXAWMQOIB-UHFFFAOYSA-N Cc1ccccc1S([n]1c2cccc(CN3CCNCC3)c2cc1)(=O)=O Chemical compound Cc1ccccc1S([n]1c2cccc(CN3CCNCC3)c2cc1)(=O)=O JCCDLZXAWMQOIB-UHFFFAOYSA-N 0.000 description 1
- FJZMECMOGGQETC-UHFFFAOYSA-N O=S(c1ccccc1)([n](cc1)c2c1c(CCCCc1ccccc1)ccc2)=O Chemical compound O=S(c1ccccc1)([n](cc1)c2c1c(CCCCc1ccccc1)ccc2)=O FJZMECMOGGQETC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0601459 | 2006-07-03 | ||
| SE0601459-1 | 2006-07-03 | ||
| US86114606P | 2006-11-27 | 2006-11-27 | |
| US60/861,146 | 2006-11-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009103313A RU2009103313A (ru) | 2010-08-10 |
| RU2449990C2 true RU2449990C2 (ru) | 2012-05-10 |
Family
ID=38561947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009103313/04A RU2449990C2 (ru) | 2006-07-03 | 2007-07-03 | Индолы в качестве модуляторов 5-ht6 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7812017B2 (https=) |
| EP (1) | EP2046741B1 (https=) |
| JP (1) | JP5324437B2 (https=) |
| CN (1) | CN101484420B (https=) |
| AU (1) | AU2007271188B2 (https=) |
| BR (1) | BRPI0712898A2 (https=) |
| CA (1) | CA2655694C (https=) |
| ES (1) | ES2398299T3 (https=) |
| NZ (1) | NZ573371A (https=) |
| RU (1) | RU2449990C2 (https=) |
| WO (1) | WO2008003703A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009006077A (es) * | 2007-01-08 | 2009-06-17 | Suven Life Sciences Ltd | Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6. |
| US20100041669A1 (en) * | 2007-01-08 | 2010-02-18 | Venkata Satya Nirogi Ramakrishna | 4-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
| WO2012064744A2 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
| WO2013050795A1 (en) * | 2011-10-03 | 2013-04-11 | Femtonics Kft. | Use of photoactive compounds |
| US10266490B2 (en) | 2012-03-16 | 2019-04-23 | Georgetown University | Radioprotector compounds |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| EP2844260A4 (en) * | 2012-04-30 | 2016-06-29 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
| EP2844259A4 (en) * | 2012-04-30 | 2015-11-11 | Anderson Gaweco | MMR MODULATORS AND USES THEREOF |
| EA027113B1 (ru) * | 2012-05-04 | 2017-06-30 | Новартис Аг | Регуляторы пути комплемента и их применение |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| JP6242868B2 (ja) | 2012-05-08 | 2017-12-06 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物 |
| WO2013169704A2 (en) | 2012-05-08 | 2013-11-14 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| WO2014133059A1 (ja) | 2013-02-28 | 2014-09-04 | 武田薬品工業株式会社 | スルホニルクロライド化合物の製造法 |
| US9475806B2 (en) | 2013-03-14 | 2016-10-25 | Novartis Ag | Complement factor B inhibitors and uses there of |
| EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| BR112016008258A2 (pt) | 2013-10-15 | 2017-10-10 | Janssen Pharmaceutica Nv | moduladores de ror?t de quinolinila |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| CN105849090A (zh) | 2013-10-30 | 2016-08-10 | 诺华股份有限公司 | 2-苄基-苯并咪唑补体因子b抑制剂及其用途 |
| EP3083588B1 (en) | 2013-12-20 | 2020-12-09 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
| US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| JP2017507950A (ja) | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
| JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| EP3166924B1 (en) * | 2014-07-08 | 2019-02-20 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| CN105367472B (zh) * | 2014-08-12 | 2020-04-21 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
| CN105367473B (zh) * | 2014-08-12 | 2020-02-11 | 广东东阳光药业有限公司 | 吲哚啉类衍生物及其在药物上的应用 |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| AU2016276947A1 (en) | 2015-06-11 | 2017-12-14 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| JP2018535958A (ja) | 2015-10-27 | 2018-12-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用 |
| EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
| CN107935905B (zh) * | 2017-11-28 | 2021-09-17 | 大理大学 | Indiacens A的合成方法 |
| CN111362859B (zh) * | 2020-03-16 | 2021-05-11 | 东莞市东阳光新药研发有限公司 | 芳杂环类衍生物的盐及其用途 |
| WO2022092247A1 (ja) * | 2020-10-30 | 2022-05-05 | 第一三共株式会社 | ３－メチル－４－ハロ－インドール誘導体の製造方法 |
| CN114870018A (zh) * | 2022-05-12 | 2022-08-09 | 江南大学 | 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2341549A (en) * | 1998-09-15 | 2000-03-22 | Merck Sharp & Dohme | Indole and indoline derivatives as 5-HT6 selective ligands |
| US6133287A (en) * | 1998-03-24 | 2000-10-17 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-HT6 affinity |
| EP1204662B1 (en) * | 1999-08-12 | 2004-06-02 | NPS Allelix Corp. | Azaindoles having serotonin receptor affinity |
| EP1648443A1 (en) * | 2003-07-30 | 2006-04-26 | Laboratorios Del Dr. Esteve, S.A. | 1-sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI970310L (fi) | 1994-07-26 | 1997-01-24 | Pfizer | 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina |
| KR100823908B1 (ko) | 2000-10-20 | 2008-04-21 | 바이오비트럼 에이비(피유비엘) | 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도 |
| WO2002041889A2 (en) | 2000-11-24 | 2002-05-30 | Smithkline Beecham P.L.C. | Indolsulfonyl compounds useful in the treatment of cns disorders |
| ES2268113T3 (es) | 2001-06-15 | 2007-03-16 | F. Hoffmann-La Roche Ag | Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6. |
| CA2485725A1 (en) | 2002-06-05 | 2003-12-18 | F. Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
| SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
| EA016456B1 (ru) * | 2006-10-30 | 2012-05-30 | Биовитрум Аб (Пабл) | 8-СУЛЬФОНИЛ-1,3,4,8-ТЕТРАГИДРО-2Н-[1,4]ОКСАЗЕПИНО[6,7-e]ИНДОЛЬНЫЕ ПРОИЗВОДНЫЕ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ 5-НТРЕЦЕПТОРНЫХ ЛИГАНДОВ |
-
2007
- 2007-07-03 CA CA2655694A patent/CA2655694C/en not_active Expired - Fee Related
- 2007-07-03 RU RU2009103313/04A patent/RU2449990C2/ru not_active IP Right Cessation
- 2007-07-03 AU AU2007271188A patent/AU2007271188B2/en not_active Ceased
- 2007-07-03 WO PCT/EP2007/056690 patent/WO2008003703A1/en not_active Ceased
- 2007-07-03 EP EP07787013A patent/EP2046741B1/en active Active
- 2007-07-03 ES ES07787013T patent/ES2398299T3/es active Active
- 2007-07-03 BR BRPI0712898-3A patent/BRPI0712898A2/pt not_active IP Right Cessation
- 2007-07-03 CN CN200780024768.0A patent/CN101484420B/zh not_active Expired - Fee Related
- 2007-07-03 JP JP2009517258A patent/JP5324437B2/ja not_active Expired - Fee Related
- 2007-07-03 NZ NZ573371A patent/NZ573371A/en not_active IP Right Cessation
- 2007-07-03 US US11/824,939 patent/US7812017B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133287A (en) * | 1998-03-24 | 2000-10-17 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-HT6 affinity |
| GB2341549A (en) * | 1998-09-15 | 2000-03-22 | Merck Sharp & Dohme | Indole and indoline derivatives as 5-HT6 selective ligands |
| EP1204662B1 (en) * | 1999-08-12 | 2004-06-02 | NPS Allelix Corp. | Azaindoles having serotonin receptor affinity |
| EP1648443A1 (en) * | 2003-07-30 | 2006-04-26 | Laboratorios Del Dr. Esteve, S.A. | 1-sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007271188B2 (en) | 2012-11-01 |
| CA2655694C (en) | 2014-12-16 |
| CN101484420B (zh) | 2014-04-30 |
| CN101484420A (zh) | 2009-07-15 |
| JP5324437B2 (ja) | 2013-10-23 |
| NZ573371A (en) | 2011-01-28 |
| US20080032968A1 (en) | 2008-02-07 |
| RU2009103313A (ru) | 2010-08-10 |
| HK1129108A1 (en) | 2009-11-20 |
| BRPI0712898A2 (pt) | 2013-01-08 |
| JP2009541461A (ja) | 2009-11-26 |
| WO2008003703A1 (en) | 2008-01-10 |
| EP2046741B1 (en) | 2012-10-31 |
| AU2007271188A1 (en) | 2008-01-10 |
| EP2046741A1 (en) | 2009-04-15 |
| US7812017B2 (en) | 2010-10-12 |
| CA2655694A1 (en) | 2008-01-10 |
| ES2398299T3 (es) | 2013-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2449990C2 (ru) | Индолы в качестве модуляторов 5-ht6 | |
| JP5132649B2 (ja) | スルホンアミド誘導体類と、その製造方法及び医薬としての応用 | |
| US20060142269A1 (en) | New compounds | |
| US20060148818A1 (en) | Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders | |
| WO2008147812A2 (en) | 4' substituted compounds having 5-ht6 receptor affinity | |
| US8138333B2 (en) | Sulfonyl-indole derivatives | |
| US7960374B2 (en) | Tricyclic compounds, compositions, and methods useful in the treatment or prophylaxis of 5-HT6 receptor-related disorders | |
| WO2006062481A1 (en) | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . | |
| CN101611028B (zh) | 取代的羟吲哚衍生物、以及它们用作加压素受体配体的用途 | |
| HK1129108B (en) | Indoles as 5-ht6 modulators | |
| NZ577103A (en) | 8-Sulfonyl-1,3,4,8-tetrahydro-2H-[1,4]oxazepino[6,7-e]indole derivatives and their use as 5-HT6 receptor ligands | |
| KR20070020373A (ko) | 5-ＨＴ6 수용체-관련 장애의 치료에 유용한 신규한 테트라히드로스피로｛피페리딘-2,7'-피롤로[3,2-ｂ]피리딘｝ 유도체 및 신규한 인돌 유도체 | |
| HK1134819A (en) | Tricyclic isoquinoline derivatives for treatment of obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150704 |